Akebia Therapeutics (AKBA) Inventory (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Inventory data on file, last reported at $13.0 million in Q1 2026.

• Inventory for Q1 2026 came in at $13.0 million, down 34.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.0 million (down 34.14% YoY), and the FY2025 annual result was $15.6 million, down 3.9% from the prior year.
• Inventory eased to $13.0 million in Q1 2026 per AKBA's latest filing, from $15.6 million in the prior quarter.
• Over five years, Inventory peaked at $45.2 million in Q3 2022 and troughed at $13.0 million in Q1 2026.
• A 5-year average of $23.1 million and a median of $20.4 million in 2023 frame the typical range for Inventory.
• The sharpest annual moves came in 2022 and 2023: Inventory surged 34.3% in 2022, then tumbled 59.24% in 2023.
• A 5-year view of Inventory shows it stood at $21.6 million in 2022, then decreased by 27.25% to $15.7 million in 2023, then grew by 3.52% to $16.2 million in 2024, then fell by 3.9% to $15.6 million in 2025, then slipped by 16.75% to $13.0 million in 2026.
• Business Quant data shows AKBA's Inventory at $13.0 million in Q1 2026, $15.6 million in Q4 2025, and $18.6 million in Q3 2025.